Skip to main content
Chison Medical Technologies Co.,Ltd. logo

Chison Medical Technologies Co.,Ltd. — Investor Relations & Filings

Ticker · 688358 ISIN · CNE1000076R4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 686 across all filing types
Latest filing 2023-04-18 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688358

About Chison Medical Technologies Co.,Ltd.

https://www.chison.com/

Chison Medical Technologies Co.,Ltd. specializes in the research, development, and manufacturing of diagnostic ultrasound systems. The company offers a comprehensive portfolio of medical imaging solutions, including trolley-based color Doppler systems, portable ultrasound units, and specialized handheld devices. Its products integrate advanced imaging technologies such as 4D imaging, artificial intelligence-assisted diagnostics, and high-resolution transducers to support clinical applications in cardiology, obstetrics, gynecology, and point-of-care settings. Chison focuses on delivering high-performance diagnostic tools to healthcare providers, supported by a global network of research centers and distribution channels. The company emphasizes continuous innovation in digital signal processing and transducer technology to enhance diagnostic accuracy and clinical workflow efficiency.

Recent filings

Filing Released Lang Actions
国金证券股份有限公司关于无锡祥生医疗科技股份有限公司2022年度募集资金存放与使用情况的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from Guojin Securities Co., Ltd. regarding the 2022 annual fundraising funds deposit and usage of Wuxi Xiangsheng Medical Technology Co., Ltd. It includes specific data on fundraising amounts, usage, storage, management, investment projects, and cash management related to the fundraising funds. The document references regulatory guidelines and includes audit and supervisory opinions. The content focuses on the management and use of raised capital funds, consistent with a capital/financing update rather than a full annual report or audit report. The document length is 7647 characters, which is substantial and contains detailed financial and operational data about fundraising usage, not just an announcement or certification. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2023-04-18 Chinese
祥生医疗第二届监事会第十六次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Wuxi Xiangsheng Medical Technology Co., Ltd. It details the approval of various reports and proposals related to the company's 2022 annual report, financial statements, profit distribution, internal control evaluation, fundraising usage, and other governance matters. The document references the 2022 annual report and other related reports but does not contain the full reports themselves. It also mentions that these items will be submitted to the shareholders' meeting for approval. The document length is 4226 characters, which is relatively short and mainly serves as an announcement of the Supervisory Board's resolutions rather than the full reports. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is an official announcement of supervisory board meeting resolutions and approvals, not the actual annual report or financial statements.
2023-04-18 Chinese
祥生医疗关于预计2023年度日常关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the expected daily related-party transactions for the fiscal year 2023 by Wuxi Xiangsheng Medical Technology Co., Ltd. It details the nature, amount, and approval process of these related-party transactions, including independent directors' opinions and the sponsor's verification. The document does not contain financial statements or comprehensive financial data but rather focuses on disclosure of related-party transactions and compliance with regulatory requirements. It is not a full financial report, earnings release, or management discussion. It is a regulatory announcement about related-party transactions, which fits best under Regulatory Filings (RNS). The document length is 3155 characters, relatively short and focused on compliance disclosure rather than a full report.
2023-04-18 Chinese
容诚会计师事务所（特殊普通合伙）关于无锡祥生医疗科技股份有限公司募集资金年度存放与使用情况鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as a "募集资金年度存放与使用情况鉴证报告" which translates to "Annual Verification Report on the Storage and Use of Raised Funds." It is issued by an accounting firm and addresses the company's 2022 annual report on the storage and actual use of raised funds. The document includes detailed financial data on the raised funds, their management, usage, and compliance with regulatory requirements. It also contains an auditor's verification conclusion and a special verification report by the sponsor institution. The content is focused on the audit and verification of the use of raised funds rather than a full annual report or interim financial report. This matches the description of an Audit Report / Information (AR) which includes standalone audit reports and applied accounting principles related to specific financial aspects, excluding full annual reports. The document is substantive and detailed, not a mere announcement or certification letter, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA). Therefore, the best classification is AR (Audit Report / Information). FY 2022
2023-04-18 Chinese
无锡祥生医疗科技股份有限公司关于2022年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2022 年度内部控制评价报告' which translates to '2022 Annual Internal Control Evaluation Report'. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2022, including financial and non-financial internal control defects, their identification, and remediation status. The document is a detailed report on internal control evaluation, which is typically considered an audit-related report rather than a full annual report. It does not contain full financial statements or comprehensive annual performance data, but focuses on internal control assessment and audit opinions related to internal controls. This fits the definition of an Audit Report / Information (AR) rather than an Annual Report (10-K) or Regulatory Filing (RNS). The document length is 3852 characters, which is relatively short but contains substantive content on internal control evaluation, not merely an announcement or certification. Therefore, the best classification is AR with high confidence. FY 2022
2023-04-18 Chinese
祥生医疗关于使用部分暂时闲置募集资金及自有资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Wuxi Xiangsheng Medical Technology Co., Ltd. regarding the use of temporarily idle raised funds and own funds for cash management. It details the board meeting resolutions, investment purpose, investment products, risk control measures, and includes independent directors' and supervisory board opinions as well as the sponsor's verification opinion. The document references regulatory guidelines on the management and use of raised funds and confirms compliance with these regulations. It does not contain financial statements or detailed financial performance data but rather discloses a specific financing-related operational decision. The document length is 4415 characters, which is relatively short and focused on a specific capital management update rather than a full financial report or earnings release. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2023-04-18 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.